Evista (raloxifene) is now approved to TREAT osteoporosis
Evista (raloxifene) is now approved to TREAT osteoporosis...it used to be approved only for PREVENTION.
Evista is a "selective estrogen." It acts like estrogen to prevent bone loss...but it doesn't stimulate the uterus or breast.
New research shows that Evista decreases vertebral fractures up to 50%...in postmenopausal women who take it for 3 years.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote